Advancing Next Generation of Antibody-based therapeutics



David Shanahan
Member of the Board

After more than 20 years in the private sector running diverse businesses throughout Texas, David Shanahan stepped into the leadership role at the Mary Crowley Cancer Research Centers in 2004. As Mary C. Crowley’s grandson, he benefited from first-hand experience watching Mary in action as she implemented her philosophy for running a business. Since starting and successfully selling his first business enterprise while in college, Mr. Shanahan proceeded to serve as founder, lead investor, and chief executive of many successful businesses in various fields. Trained as an electrical engineer, Mr. Shanahan brings a highly analytical mind coupled with an uncommon heart to honor God and serve others to his role at Mary Crowley. He voluntarily assumed leadership and immediately began to use his creative entrepreneurial skills to magnify the excellence, care and commitment that continue to improve the quality and scientific excellence of cancer care. In record time, he has advanced a personal mission to expedite approaches that are transformative and potentially curative, defining the next generation of personalized medicine in cancer care. In 2005, he founded Gradalis, Inc., a biotech startup company manufacturing personalized cancer therapies for use in clinical trials. Today, David Shanahan lives out his grandmother’s legacy as he executes the convergence of pioneering science while committing his personal time and resources to support the needs of today's cancer patients.

Sanjay Khare, PhD
Member of the Board

Dr. Sanjay Khare is President and CEO, Chairman of the Board of ImmunGene Inc.. Prior to founding ImmunGene, Dr. Khare was Scientific Director at Amgen Inc. He joined Amgen in 1999 and led several inflammation drug discovery programs. Dr. Khare received his Ph.D. in Immunology at the All-India Institute of Medical Sciences, New Delhi, India. With his passion in Immunology research, Dr. Khare joined as postdoctoral fellow in the Immunology department at the Mayo Clinic and studied humanized mouse model systems. He is recipient of ASHI scholar award in 1997. Dr. Khare coauthored more than 35 scientific papers, edited a book on TNF superfamily and presented seminars in scientific conferences. Dr. Khare has several patents and led research teams at Amgen and his team delivered several clinical candidates. He has served as consultant to start-up biotech companies for their R&D activities.

Mike Gresser, PhD
Member of the Board

Dr. Mike Gresser received his Ph.D in Biochemistry in 1976 from Brandeis University. He did postdoctoral studies at the Molecular Biology Institute at UCLA under the supervision of Paul D. Boyer. In 1980 Mike joined the Department of Chemistry at Simon Fraser University in Burnaby, British Columbia, and progressed to Professor of Chemistry. While there Mike received the Excellence in Teaching Award, and did research on the biochemistry of Vanadium V, and on the mitochondrial ATPase. In 1988 Mike Joined the Merck Frosst Center for Therapeutic Research in Kirkland, Quebec as Director of Biochemistry. Over the next twelve years Mike progressed through the ranks of Senior Director, then Executive Director of Biochemistry and Molecular Biology. Mike’s team worked on a variety of small molecule drug discovery programs, resulting in the introduction of numerous molecules into clinical trials. Two of these molecules, Singulair and Vioxx, became products. In 2000 Mike joined Amgen Inc. in Thousand Oaks, California, as Vice President of Research for Inflammation, where he remained until April, 2006. For two years Mike served as Head of Neuroscience Research as well as Inflammation Research. Mike’s team at Amgen worked on taking many molecular targets, introducing numerous small molecules, human antibodies and other proteins into development. Currently Mike is a Visiting Scholar at the Molecular Biology Institute at UCLA, and works as a consultant with Clarity Therapeutics Consulting.